Background: Pathology-generated equations have been introduced to predict Oncotype DX recurrence score (ORS) in breast cancer. The purpose of the study is to improve these equations.
T raditionally, the surgical pathology evaluation of the tumor provides prognostic information, including tumor size, histologic type, Nottingham grade, lymph node status, and biomarkers profile [estrogen receptor (ER), progesterone receptor (PR), and HER2]. 1, 2 Whereas HER2-positive patients are offered anti-HER2targeted therapy, patients with triple-negative cancers are usually treated with chemotherapy. ER-positive breast cancer is normally treated with hormonal therapy. However, subset of these patients who have more aggressive disease benefit from adjuvant chemotherapy. There have been many attempts to recognize this subset; Oncotype DX assay provided by Genomic Health (Redwood City, CA) is the most widely used test to answer that specific question.
Oncotype DX assay is a quantitative reverse transcription-polymerase chain reaction (RT-PCR)-based assay usually offered to patients who have node-negative and ER-positive invasive breast cancer. The assay calculates the Oncotype recurrence score (ORS) based on the expression of 21 genes, 16 of which are cancer related. The score ranges from 0 to100 and the results are divided into 3 risk categories: low <18, intermediate 18 to 30, and high >30. These scores were validated using formalinfixed paraffin-embedded tissue blocks from the tamoxifen-treated arm of the National Surgical Adjuvant Breast and Bowel Project clinical trial B-14. 3 Tissue blocks from the National Surgical Adjuvant Breast and Bowel Project clinical trial B-20 were used to perform the Oncotype DX assay and calculate the ORS for each patient. Patients with high ORS were shown to benefit from adjuvant chemotherapy, whereas patients with low ORS were shown to derive minimal or no benefit. 4 It has been validated by experience from multiple studies that included several thousand patients. [5] [6] [7] [8] Although this assay seems ideal for recognizing the subset of patients who can benefit from adjuvant chemotherapy, there have been multiple issues related to its high cost ($4000) which can only be afforded by a subset of patients and its unavailability in poor countries. Moreover, a small fraction of cases get rejected by Genomic Health due to either insufficient tissue or degraded RNA. There have been multiple studies that evaluated the histomorphology and immunohistochemistry (IHC) to predict the ORS with variable success. 9, 10 These studies extracted the histologic and IHC variables from the pathology reports with a nonuniform interpretation. In addition, other studies showed that tumors enriched with stroma, even though they were traditionally known to have low risk of recurrence, had unexpectedly high ORS. 11 Therefore, we intended to uniformly review the histologic slides and evaluate multiple histomorphologic parameters to improve the already published equations with resulting benefit to patients with ER-positive breast cancers.
MATERIALS AND METHODS

Cases and Histologic Evaluation
A total of 416 (test set) consecutive breast carcinoma cases with available ORS were reviewed. The cases were from Roswell Park Cancer Institute files between 2005 and 2013. A validation set of 91 cases was prospectively reviewed at the time of assay order between 2013 and 2014. The cases were scored using the generated formulas from the test set. These cases had Oncotype DX assay based on clinical request by the treating breast oncologist. The following variables were abstracted from the pathology report: tumor size, Nottingham grade (designated as reported Nottingham grade, see below), ORS, ER, and PR Allred scores, and HER2 status. ER and PR were assessed semiquantitatively by using the Allred scoring method. This method incorporates intensity and distribution of reactivity. 12 HER2 immunohistochemical results were reported according to the College of American Pathologist/ American Society of Clinical Oncology guidelines. 13 The corresponding hematoxylin and eosin slide to the tested tissue block for each patient was reviewed and scored jointly by 2 pathologists (T.K. and X.H.). The following variables were graded and recorded: tumor necrosis, degree of tumor-infiltrating lymphocytes (TIL), and percentage of ductal carcinoma in situ. Tumor necrosis was graded from 0 to 4: grade 0 = no necrosis, grade 1 = 1 focus (a cluster of >3 cells), grade 2 = Z2 nonconnected foci of necrosis, grade 3 = Z2 connected foci but not geographic, and grade 4 = geographic necrosis. The degree of TIL was graded from 0 to 4: grade 0 = virtually no lymphocytes, grade 1 = sparse nonaggregated, grade 2 = clustered, grade 3 = sheets not obscuring the tumor, and grade 4 = sheets obscuring the tumor. Tumor/stroma ratio was visually estimated as a percentage (0% to 100%). The percentage of ductal carcinoma in situ was visually estimated from 0% to 100%.
We intended to evaluate whether uniform interpretation of Nottingham grade has better correlation with the ORS than just abstracting the reported Nottingham grade. For that we uniformly followed the Nottingham grading system. For tubular formation, a score of 1 was given when the tubular structures composed >75% of the tumor, grade 3 was given when <10% of tumor had tubular structures, and grade 2 for any value between 10% and 75%. For nuclear grading, grade 1 small monomorphic cell, grade 2 moderate nuclear variation, and grade 3 marked nuclear pleomorphism. For mitotic count, a score of 1 was given for mitotic count of 0 to 8/10 HPF, a score of 2 was given for a mitotic count of 8 to 17/10 HPF, and a score of 3 was given for mitotic count of >17/10 HPF with area measuring 0.237 mm 2 (BX 45 Microscope; Olympus, Tokyo, Japan). Then to obtain the overall tumor grade the scores of each category were added together, giving a possible total of 3 to 9. Tumor grade was then allocated on the following basis: 3 to 5 points grade I, 6 to 7 points grade II, and 8 to 9 points grade III. 2 The study was conducted after the approval of RPCI Institutional Review Board #EDR 241113. As the study included only preexciting data, no patient's consent was required.
Statistical Analysis
Equations were calculated including all significant variables, one with reported Nottingham grade, one with current Nottingham grade, and one with current Nottingham grade and other histopathologic variables. The Pearson correlation coefficient r and coefficient of determination r 2 were used for continuous variables, whereas the Spearmen rank correlation coefficient was used for categorical variables. Table 1 illustrates the distribution of clinicopathologic variables in the test set according to ORS. The following variables were significantly correlated with high ORS: histologic type with no special type having higher risk than lobular, higher Nottingham grade, lower ER and PR expression, amplified HER2, higher degree of necrosis (Figs. 1A-D), and higher degree of TIL (Figs. 1E-H). In addition, higher tumor/stroma ratio correlated with higher ORS (Figs. 1I-L). When we performed the regression analysis, we found that all of the above variables significantly correlated with the ORS. However, tumor/stroma ratio did not improve the equations. Our Nottingham grading had better predictability for the ORS than the reported Nottingham grade with "r" value of 0.14 versus 0.32, respectively ( Table 2 ).
RESULTS
In the equation using the reported Nottingham grade, ER, PR, and HER2, the overall concordance with the ORS was 64.86%. After excluding the intermediate category detected by the formula, the concordance rate was 95.28% ( Fig. 2A ). When the current Nottingham grade was used instead of the reported Nottingham grade, the concordance rate became 69.61% and 98.62%, respectively ( Fig. 2B ). When the histologic variables were added to the previous equation, we found tumor necrosis and TIL improved this equation. The rates became 70.1% and 98.63%, respectively (Fig. 2C ).
This equation was produced: ORS = 49.409À 2.226Â ERÀ 1.633Â PR+(À 8.655 for Her2 negative, 0 for Her2 positive)+(0 for Nottingham Grade 1, 1.232 for Nottingham Grade 2, 9.346 for Nottingham Grade 3)+2.205Â Necrosis+2.423Â TIL.
The total number of patients who had either low or high RS using our formula was 291 of 408 (71.3%) ( Table 3 ). Only 3 patients were misclassified as having low RS using our formula instead of high RS using Oncotype DX assay. The characteristics of these 3 patients are listed in Table 4 . In the equation using ER, PR, HER2, and Nottingham grade, the concordance rate for the validation set was 72.53% and 100%, respectively ( Table 5) . Adding necrosis and TIL did not improve the concordance rate.
Comparing With New Magee Equation
To compare with Magee equation, we referred to their equation that included tumor size, Nottingham grade, and ER/PR/HER2. The correlation with ORS was 59.4% (overall) and 100% (after excluding the intermediate category). 10 The distribution of cases in our cohort in terms of ORS low, intermediate, and high was 54%, 35%, 10%, and in Klein's study was 46%, 41%, 11%, respectively. Therefore, there were less cases with intermediate ORS and more cases with low ORS in our data than in Klein's data. To examine this factor, we randomly select cases to match Klein's data. We included 351 cases from the original data with the ORS distribution for low, intermediate, and high ORS, 165 (47%), 147 (41.9%), and 39 (11.1%), respectively. Then we calculated the concordance rate. They became 68.6% and 98.19%, respectively.
Subset Analysis Based on Nottingham Grade and PR Levels
We divided the data (test set) into 6 subgroups based on Nottingham grade (1, 2, and 3) and PR Allred score (Z5 and <5). We found that 3 of 144 (2.08%) cases with Nottingham grade 1 and PRZ5 had high ORS. All 26 cases with Nottingham grade 3 and PR < 5 had intermediate (15.38%) or high (84.62%) ORS ( Table 6 ). Two of the 3 patients who had high ORS with low Nottingham grade and high PR score had HER2 gene amplification and treated with Herceptin. All 3 patients had positive lymph node and axillary lymph node dissection. One patient had low PR using RT-PCR (5.7) ( 
DISCUSSION
A large subset of patients with ER-positive, nodenegative breast cancer do not benefit from chemotherapy.
To identify this subset, multiple assays have been introduced into the market, with most widely used being Oncotype DX. This assay has been shown to correlate with the clinical outcome through multiple prospective studies. [3] [4] [5] [6] [7] [8] We recently found good correlation between Oncotype DX assay and IHC in detecting ER and PR status. 14 Other studies have shown considerable discordance particularly for HER2 amplification. 15 For many patients the information about benefits of chemotherapy can be obtained by merely examining multiple histopathology variables, which would allow many more women to avoid unnecessary and toxic treatments. There have been multiple studies showing good correlation between ORS and the pathologic-generated equations in the past, although in this study we present improvement over. 9, 10 One of these equations is the new Magee equation. The correlation with ORS was 59.4% (overall) and 100% (after excluding the intermediate category). 10 When we compared our equation including the same variables, the rate of concordance was 69.61% and 98.62%, respectively. There was significant difference in the rate of concordance between the 2 equations for the overall cases (59.4% vs. 69.61%). There are 2 possible reasons for this difference. The first reason is possibly due to our consistent review of the histologic slides and grading the tumor rather than extracting the Nottingham grade from the pathology report. In fact, when we included the reported Nottingham grade in the equation, the concordance rate was 64.86% and 95.28%, respectively. The other reason is possibly due to the difference in the distribution of the ORS (low, intermediate, high) between the 2 studies. After randomly selecting cases from our cohort to match Klein's data, the rates became 68.6% and 98.19%, respectively. These rates were slightly less than the rates when all cases were included, but our equation continued to perform significantly better than the new Magee equation. Therefore, we conclude that consistent review of the histologic slides could improve the existing equations.
It is known that there is a degree of interobserver variability in interpreting Nottingham grading. Fireson et al 16 found a substantial agreement for tubule formation, moderate agreement for mitotic count, and nearmoderate agreement for nuclear pleomorphism. We found variability between the current and reported Nottingham grade. Whereas the "r" value for the first was 0.32, it was 0.14 for the second (Table 2 ). This is considered a disadvantage of this equation or any equation that Nottingham grading is part of. Oncotype DX assay has the advantage of being more reproducible.
To use this formula in clinical practice, we recommend excluding cases that have intermediate RS. The total number of patients who had low or high RS using our formula was 291. Currently, the cost of 1 Oncotype DX assay is about $4000. 17 Therefore, in the period of the study of 8 years, by using our formula we could have saved 291 Â $4000 = $1,164,000.00 for the health care industry. However, the down side of this application is Alive and disease free (21 mo) Alive and disease free (24 mo) Bone metastases (28 mo) Alive after 57 mo *Interpretation (ER negative <6.5, positive Z6.5; PR negative <5.5, positive Z5.5). wDeclined chemotherapy. ALD indicates axillary lymph node dissection; ER, estrogen receptor; mi, micrometastases ( > 0.2 and <2 mm); IC NST, invasive carcinoma no special type; IHC, immunohistochemistry; ILC, invasive lobular carcinoma; ORS, Oncotype Dx recurrence score; PR, progesterone receptor; RS, Recurrence Score; RT-PCR, reverse transcription-polymerase chain reaction; TIL, tumor-infiltrating lymphocytes. that a very small fraction of patients [3 of 291 (< 1%)] could have been misclassified as having low RS, while actually they have high RS. It is also worth noting that 2 patients (#1 and #2, Table 4 ) had positive lymph nodes. The Oncotype DX was validated for node-negative patients, making the ORS questionable. The third patient (#3, Table 4 ) did not respond to chemotherapy and developed distant metastases. PR is one of the major genes in ORS. We found discordance between these 2 assays in 1 patient (#2), and 1 patient (#1) had intermediate Allred score of 6 and low RT-PCR result (5.7). We have found previously that PR had higher discordance (positive vs. negative) between these 2 assays than ER does. 14 This discordance might have played a role in the overall RS. This low-cost formula would also allow clinicians in other parts of the world where Oncotype DX assay is not available, to provide their patients with the information to make best clinical decisions. Acs et al 11 found that cellular stroma and/or inflammatory cells associated with the tumor cells may contribute to intermediate or high ORS in low-grade invasive breast carcinomas. It is known that when the tissue undergoes Oncotype DX assay the samples are macrodissected, which includes stroma and intimate inflammatory cells. When the stroma and/or inflammatory cells are mitotically active, the ORS would be falsely higher. [18] [19] [20] In our study we separated the degree of TIL from the proportion of tumor/stroma. The reason for this separation was that the stroma of many cases with high stromal proportion was paucicellular. Tumors with paucicellular stroma-mitotically inactive-would not contribute in increasing the ORS. Therefore, this separation would help identifying each component's (inflammatory cells vs. stroma) contribution in the ORS. We found that low stromal component being predictor of higher ORS. That is possibly due to the fact that many of the cases that had higher stromal proportion were paucicellular and therefore mitotically inactive which would not contribute to a high ORS (Figs. 1I, J). We noticed that many of the tumors that had high tumor/stroma ratio also had high Nottingham grade and tumors with low tumor/stroma ratio had low Nottingham grade. When we performed the Pearson correlation between tumor/stroma ratio and Nottingham grade, we found strong correlation (r = 0.32, r 2 = 0.11, P-value <0.01). There was no correlation between tumor/stroma ratio with other adverse factors such as ER and PR expression. That is why when we performed the regression analysis we found that tumor/stroma ratio did not improve our equation.
We also found that higher degree of TIL and tumor necrosis predicted higher ORS. TIL has been found to indicate a better prognosis for many solid organ malignancies. 21 The possible reason for this discordance is that the macrodissected tumor tested with Oncotype DX is contaminated with mitotically active lymphocytes, consistent with what Acs et al 11 found. However, the more likely explanation is that presence of TIL is indicative of genetic instability. Therefore, it is indicative of higher proliferation rate of the tumor itself and presence of multiple tumor antigens. 22 This finding correlates with the high ORS and benefit from chemotherapy. We believe that as the TIL scoring methods become standardized it will become a valuable tool in helping clinicians make treatment decisions. To minimize intraobserver and in- terobserver variability, we used infiltration pattern rather than TIL percentage. The latter has been suggested by the International TILs Working Group 2014. 23 It has been proven that tumor necrosis is an independent prognostic predictor for early recurrence and death in breast cancer. 24 Therefore, we thought of examining its role in independently predicting the ORS. We found not only the presence of necrosis predicting high ORS but also the degree of necrosis. In the validation set, necrosis and TIL did not improve the concordance rate. We think that is due to the small number of cases with high OSR (n = 7). We conclude that adding both tumor necrosis and TIL improve the equation.
Allison and colleagues investigated into the possibility of using subset analysis rather than a new equation to predict the ORS. They divided their data into 6 subgroups based on Nottingham grade (1, 2, and 3) and PR Allred score (Z5 and <5). They found that all cases (n = 26) with Nottingham grade 1 and PR Allred score Z5 had intermediate (n = 7) or low ORS (n = 19). Similarly, all cases (n = 5) with Nottingham grade 3 and PR Allred score <5 had intermediate (n = 1) or high (n = 4) ORS. 25 We performed a similar analysis. We found that 3 of 144 (2.08%) cases had high ORS in the first category. We also found that none of the 26 patients had low ORS in the second category ( Table 6 ). The partial discordance between Allison's and our study is possibly due to our higher numbers of included cases in each category (144 vs. 26 and 26 vs. 5). The vast majority of patients with Nottingham grade 1 and PR Allred score Z5 had low or intermediate ORS, whereas all patients who had Nottingham grade 3 and PR Allred score <5 had intermediate or high ORS. It is worth noting that the categorization suggested by Allison and colleagues misclassified 3 of 144 (2.08%) patients. Using our formula and including all cases, we misclassified 3 of 291 (< 1%) of the patients. Therefore, we conclude that our formula is better than subcategorizing patients based on Allison and colleagues' proposal.
We conclude that our equation validated the Magee equation. Moreover, consistently interpreting Nottingham grade and incorporating tumor necrosis and TIL have shown to improve our equation. However, it should be noted that when more variables are added to any given equation, the reproducibility becomes weaker, which may negate this improvement. Our study is limited by the fact that the validation set was too small and had small number of cases with necrosis or high TIL. Therefore, additional studies with larger number of cases are needed to test the benefit of adding tumor necrosis and TIL to the equation.
